NPPB and hydrops fetalis: A post-hoc analysis showed that patients with a 30% reduction in NT-proBNP at time of randomization had the lowest prevalence of HF readmission or death (28%) at 6 months whereas those patients who did not have a 30% reduction but subsequently achieved it with guided therapy had a higher prevalence of HF readmission or death (49%) at 6 months, but this was still lower than patients who were unable to obtain a 30% reduction in NT-proBNP who had the highest prevalence of HF readmission or death (59%) at 6 months.